Vaccines in Adults

Dr. Lemuel Martinez-Bonilla, MD, FIDSA
Infectious Disease Specialist
Vaccines
Continued Medical Education

History Review
Review history and evolution of vaccines

Strategies
Understand vaccine benefits for your patients

Solutions
How to educate yourself and the patients

Success
Allow your patients to prepare their immune system and extend their life expectancies
Green marketing is a practice whereby companies seek...
FIGURE 1. Crude death rate* for infectious diseases — United States, 1900–1996†

- 40 States Have Health Departments
- Influenza Pandemic
- Last Human-to-Human Transmission of Plague
- First Continuous Municipal Use of Chlorine in Water in United States
- First Use of Penicillin
- Salk Vaccine Introduced
- Passage of Vaccination Assistance Act
FIGURE 2. The 10 leading causes of death as a percentage of all deaths — United States, 1900 and 1997

1900

- Pneumonia
- Tuberculosis
- Diarrhea and Enteritis
- Heart Disease
- Stroke
- Liver Disease
- Injuries
- Cancer
- Senility
- Diphtheria

Percentage
Where we stand "today"

1997

- Heart Disease
- Cancer
- Stroke
- Chronic Lung Disease
- Unintentional Injury
- Pneumonia and Influenza
- Diabetes
- HIV Infection
- Suicide
- Chronic Liver Disease

Percentage
Immunization is one of the most effective preventive health measures.

**Vaccines**

- **Direct childhood vaccination**: Vaccination programs directly benefit the immunized child.
- **Herd immunity**: They also indirectly benefit unimmunized persons (adults and immunosuppressed patients).

**Results**
- Decrease incidence of pneumonia in adults

**Requirements**
- A large portion of the population must be vaccinated.

**90%**

Preventable diseases decreased by 90%
Herd Immunity
Adult Vaccination

**Benefit**
Community immunity protects children who are too young for immunization and persons with contraindications to vaccines.

**Prevention**
Of paramount importance to the ever increasing population of patients who have impaired immunity, because of excessive morbidity and mortality, and antimicrobial therapy is often less effective than usual.

**Requirement**
It relies on the majority of the population receiving routinely recommended immunizations.

**Protection of the vulnerable**
Many patients with impaired immunity are unable to mount a protective immune response to active vaccination. Failure to adhere to the recommended immunization schedules, leaves individuals susceptible to life-threatening diseases.
Herd Immunity: How It Works

- Percent Vaccinated: 0%
- Percent Vaccinated: 25%
- Percent Vaccinated: 50%
- Percent Vaccinated: 75%
- Percent Vaccinated: 90%
- Percent Vaccinated: 95%

- Infected
- Unvaccinated
- Vaccinated
Vaccination Historical Achievements

✓ Global eradication of smallpox
✓ Nearly global eradication of polio
✓ Drastic decrease in the morbidity & mortality associated with other infectious diseases

As a result, many parents are unaware of the threats that these infectious diseases posed for previous generations, and as such, may believe that vaccinations are no longer necessary for their children.

While health officials maintain that routine childhood vaccines are safe and effective, vaccination refusal has increased in the US the last decade, same as parents expressing concerns about the safety of vaccines.
Vaccination hesitancy - Adults

2016 NHIS estimates influenza vaccination among adults aged ≥19 years was 45.4% and Tdap vaccination 31.7%.

• Coverage for the adult age-appropriate composite measures including influenza and any tetanus vaccine was low in all age groups:
  ✓ 14.5% in adults aged 60-64 years
  ✓ 26.7% in adults aged 19-59 years

• Racial and ethnic differences in vaccination coverage is lower for most vaccinations among non-white compared with white adults.

• All providers should routinely assess adults’ vaccination status at every clinical encounter, strongly recommend needed vaccines.
Vaccination hesitancy - Adults

Adults are at increased risk of:

- *Particularly influenza and pneumococcal disease*
- *Compliance with adult vaccination schedule is low*
Is education the answer?

A 2014 study sought to test the effectiveness of messages designed to reduce vaccine misperceptions. 1759 parents in the US age ≥18 years with children age ≤17 and younger were surveyed. Participants were randomly assigned to a control group or received 1 of 4 interventions:

✓ Information from the Centers for Disease Control and Prevention explaining the lack of evidence that MMR causes autism
✓ Textual information from the Vaccine Information Statement about the dangers of the diseases prevented by MMR
✓ Images of children who have diseases prevented by the MMR vaccine
✓ A dramatic narrative from the CDC about an infant who almost died from measles

None of the interventions increased a parent’s desire to vaccinate a child.
Vaccination hesitancy

Parents who are faced with the decision to have their children vaccinated may be more likely to seek information about vaccines via the Internet than through their doctor.

Perceiving danger in vaccines tends to be associated with reluctance to vaccinate. For example, many people believe that vaccines have dangerous side effects, and that exposure to the disease itself would often be preferable to the vaccination.

Now anti-vaccine group want to be referred as “vaccine risk awareness” despite all available safety data.
This is exemplified in that outbreaks of pertussis and measles are known to spread through populations where rates of vaccination refusal are high.
Vaccines Today Work Better Than Ever

1980
Protection from 7 diseases with 15,096 antigens
by the age of 4

2017
Protection from 16 diseases with only 173 antigens
by the age of 18

Based on CDC Recommended Vaccine Schedule U.S. for children birth to 18 years.
Source: Plotkin's Vaccines (Seventh Edition)

**Safe**
Current vaccines are safer and elicit better immune response.

**Available**
Available at clinics, medical offices and pharmacies

**Lead by example**
Make sure you understand vaccine benefits and vaccinate yourself. If not, most efforts will fail.
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>19–26 years</th>
<th>27–49 years</th>
<th>50–64 years</th>
<th>≥65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza inactivated (IIV) or influenza recombinant (RIV)</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
</tr>
<tr>
<td>or influenza live, attenuated (LAIV)</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
</tr>
<tr>
<td>Tetanus, diphtheria, pertussis (Tdap or Td)</td>
<td>1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (see notes)</td>
<td>1 dose Tdap, then Td or Tdap booster every 10 years</td>
<td>1 dose Tdap, then Td or Tdap booster every 10 years</td>
<td>1 dose Tdap, then Td or Tdap booster every 10 years</td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td>1 or 2 doses depending on indication (if born in 1957 or later)</td>
<td>2 doses</td>
<td>2 doses</td>
<td>2 doses</td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td>2 doses (if born in 1980 or later)</td>
<td>2 doses</td>
<td>2 doses</td>
<td>2 doses</td>
</tr>
<tr>
<td>Zoster recombinant (RZV)</td>
<td>2 doses</td>
<td>2 doses</td>
<td>2 doses</td>
<td>2 doses</td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td>2 or 3 doses depending on age at initial vaccination or condition</td>
<td>27 through 45 years</td>
<td>27 through 45 years</td>
<td>27 through 45 years</td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td>1 dose</td>
<td>1 dose</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td>1 or 2 doses depending on indication</td>
<td>1 dose</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td>2 or 3 doses depending on vaccine</td>
<td>2 or 3 doses depending on vaccine</td>
<td>2 or 3 doses depending on vaccine</td>
<td>2 or 3 doses depending on vaccine</td>
</tr>
<tr>
<td>Hepatitis B (HepB)</td>
<td>2 or 3 doses depending on vaccine</td>
<td>2 or 3 doses depending on vaccine</td>
<td>2 or 3 doses depending on vaccine</td>
<td>2 or 3 doses depending on vaccine</td>
</tr>
<tr>
<td>Meningococcal A, C, W, Y (MenACWYW)</td>
<td>1 or 2 doses depending on indication, see notes for booster recommendations</td>
<td>1 or 2 doses depending on indication, see notes for booster recommendations</td>
<td>1 or 2 doses depending on indication, see notes for booster recommendations</td>
<td>1 or 2 doses depending on indication, see notes for booster recommendations</td>
</tr>
<tr>
<td>Meningococcal B (MenB)</td>
<td>2 or 3 doses depending on vaccine and indication, see notes for booster recommendations</td>
<td>2 or 3 doses depending on vaccine and indication, see notes for booster recommendations</td>
<td>2 or 3 doses depending on vaccine and indication, see notes for booster recommendations</td>
<td>2 or 3 doses depending on vaccine and indication, see notes for booster recommendations</td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td>1 or 3 doses depending on indication</td>
<td>1 or 3 doses depending on indication</td>
<td>1 or 3 doses depending on indication</td>
<td>1 or 3 doses depending on indication</td>
</tr>
</tbody>
</table>
Adult Vaccination Recommendations

2019

Pneumococcal disease
- Prevnar 13
- Pneumovax 23

Pneumonia

Shingles
- Zovirax
- Shingrix

Varicella-Zoster

Influenza
- Recombinant
- Live attenuated
  - Trivalent
  - Tetravalent
- High dose

Flu

Tetanus
- Td
- Tdap

Tetanus/Pertusis

Human papilloma virus
- HPV

Human papilloma virus
There are several different types of vaccines. Based on a number of these factors, scientists decide which type of vaccine they will make. They include:

✓ Inactivated vaccines
✓ Live-attenuated vaccines
✓ Messenger RNA (mRNA) vaccines
✓ Subunit, recombinant, polysaccharide, and conjugate vaccines
✓ Toxoid vaccines
✓ Viral vector vaccines
Pneumococcal disease is common in young children, but older adults are at greatest risk of serious illness and death.

Invasive pneumococcal disease caused by the serotypes in PCV7 declined by 99% in the United States since 2000.

Unvaccinated people of all ages, including babies too young to get the vaccine, have seen decreases in disease.

Experts estimate PCV13 in the first 3 years of use:
✓ Prevented more than 30,000 cases of invasive pneumococcal disease
✓ Prevented 3,000 deaths
Pneumococcus vaccine

Currently 2 vaccines, Prevnar 13 and Pneumovax 23

Before 65 y/o, Pneumovax 23 only if:
  • Heart diseases
  • Lung disease

After 65 y/o, Prevnar 13 and Pneumovax 23 independent of medical conditions

When possible, PCV13 should be given first, followed by PPSV23 in 8 weeks for maximum effect. But should not wait more than a year.
Pneumococcal Vaccine-Naïve Adults

≥ Age 65

- PCV13 ≥ 8 wks → PPSV23 ≥ 5 yrs → PPSV23 ≥ 5 yrs → PPSV23

PPSV23-Immunized Adults

≥ Age 65

- PPSV23 ≥ 1 yr → PCV13 ≥ 8 wks → PPSV23 ≥ 5 yrs → PPSV23
- PPSV23 ≥ 5 yrs → PPSV23 ≥ 1 yr → PCV13 ≥ 8 wks → PPSV23
- PPSV23 ≥ 5 yrs
Both PCV13 and PPSV23 should be given to adults of any age who have the underlying conditions:

Cerebrospinal fluid leak/Cochlear implant
Functional or anatomic asplenia

Immunocompromising conditions:

- ✓ Congenital or acquired
- ✓ HIV infection
- ✓ Generalized malignancy (e.g., metastatic disease, disease treated with chemotherapy)
- ✓ Hematologic malignancy (e.g., leukemia, Hodgkin/non-Hodgkin lymphoma, multiple myeloma)
- ✓ Solid organ transplant
- ✓ Iatrogenic immunosuppression, including long-term systemic glucocorticoids or radiation
- ✓ Chronic renal failure/Nephrotic syndrome
- Prior doses count towards doses recommended below and do not need to be repeated.
- If PPSV23 was given previously: (1) Wait 1 year before giving PCV13; (2) For group B, wait at least 5 years before giving a second dose of PPSV23.
- No more than two doses of PPSV23 recommended before 65th birthday and one dose thereafter.
- DO NOT administer PCV13 and PPSV23 at the same visit.

A. Smoker, long-term care facility resident, or chronic conditions:
- Heart Disease (excluding hypertension)
- Lung Disease (including asthma)
- Liver Disease (including cirrhosis)
- Diabetes
- Alcoholism

B. Immunocompromised:
- HIV Infection
- Chronic Renal Failure
- Nephrotic Syndrome
- Asplenia (including sickle cell)

C. CSF Leaks or Cochlear Implants

PCV 13 → 8 Weeks → PPSV 23 → 5 Years → PPSV 23
Pneumococcus vaccine

Shared serotypes:
1, 4, 5, 6B, 7F, 9V, 14 (6 total)

Combined serotypes:
20 unique serotypes, but there is an immune boosting effect when combined

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Serotypes included</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPSV23</td>
<td>1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F</td>
</tr>
<tr>
<td>PCV7</td>
<td>4, 6B, 9V, 14, 18C, 19F, and 23F</td>
</tr>
<tr>
<td>PCV10</td>
<td>1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F</td>
</tr>
<tr>
<td>PCV13</td>
<td>1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F</td>
</tr>
</tbody>
</table>
Pneumococcal contraindications

Don’t get PCV13 if you have ever had a life-threatening allergic reaction to:

• A shot of the vaccine
• An earlier pneumococcal vaccine called PCV7 (or Prevnar)
• Any vaccine containing diphtheria toxoid (for example, DTaP)

Don’t get PPSV23 if you:

• Ever had a life-threatening allergic reaction to a shot of PPSV23
• Have a severe allergy to any component of the vaccine
Herpes-Zoster / Varicella-Zoster
Almost 1 out of 3 people in the United States will develop shingles in their lifetime. Most people will have it only once. However, you can get the disease more than once.

Your risk of getting shingles increases as you get older. The most common complication of shingles is postherpetic neuralgia (10-18%).

Approximately 1-4% of people are hospitalized for complications.
Herpes-zoster vaccination is indicated for individuals ≥50 years of age to reduce the risk of developing zoster and postherpetic neuralgia. Vaccination is **not** indicated for the treatment of zoster or postherpetic neuralgia.

Currently 2 vaccines:
- ✔️ A live attenuated vaccine (Zostavax)
  
  Recommended at 60, 1 dose needed

- ✔️ A non-live recombinant glycoprotein E vaccine. Sold as Shingrix.
  
  Recommended at 50, 2 doses needed
## Comparison of zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Efficacy (incidence HZ)</th>
<th>Systemic side effects that prevented normal everyday activities (vaccine versus placebo)</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ZVL (single dose)</strong></td>
<td>Population ≥60&lt;sup&gt;[1]&lt;/sup&gt;; 51% reduction in risk of HZ compared with placebo (95% CI 44.2-57.6%; 11.12 versus 5.42 per 1000 person-years)</td>
<td>&lt;1% reported in post-hoc analysis&lt;sup&gt;[5]&lt;/sup&gt;</td>
<td>3.1 years</td>
</tr>
<tr>
<td></td>
<td>Population 50 to 59&lt;sup&gt;[2]&lt;/sup&gt;; 70% reduction in risk of HZ compared with placebo (95% CI 54.1-80.6%; 6.57 versus 1.99 per 1000 person-years)</td>
<td></td>
<td>1.3 years</td>
</tr>
<tr>
<td><strong>RZV (2 doses separated by 2 months)</strong></td>
<td>Population ≥70&lt;sup&gt;[3]&lt;/sup&gt;; 89% reduction in risk of HZ compared with placebo (95% CI 84.2-93.7%; 9.2 versus 0.9 per 1000 person-years)</td>
<td>6 versus 2%</td>
<td>3.7 years</td>
</tr>
<tr>
<td></td>
<td>Population ≥50&lt;sup&gt;[4]&lt;/sup&gt;; 96.2% reduction in risk of HZ compared with placebo (95% CI 92.7-98.3%; 9.1 versus 0.3 per 1000 person-years)</td>
<td>11.4 versus 2.4%</td>
<td>3.2 years</td>
</tr>
</tbody>
</table>
Human papilloma virus
HPV is the most common sexually transmitted infection (STI). 79 million Americans are infected. About 14 million people become newly infected each year.

In most cases, HPV goes away on its own and does not cause any health problems. But when HPV does not go away, it can cause health problems like genital warts and cancer.

HPV can cause cancers including:

- Cervical
- Vulvar
- Vagina
- Penis
- Anus

It can also cause cancer in the back of the throat, including the base of the tongue and tonsils.
Human papilloma virus

• **Genital warts:** Before HPV vaccines:
  • 340,000 - 360,000 women and men were affected by genital warts yearly.
  • About 1/100 sexually active adults in the U.S. has genital warts at any given time.

• **Cervical cancer:**
  • Every year, nearly 12,000 women living in the U.S. will be diagnosed with cervical cancer
  • More than 4,000 women die from cervical cancer—even with screening and treatment.
**RATIONALE**

**Females** — Vaccination provides a direct benefit to female recipients by safely protecting against cancers that result from HPV infection. This preventive effect is most notable and best studied with cervical cancer. HPV types 16 and 18 cause approximately 70% of all cervical cancers worldwide, and HPV types 31, 33, 45, 52, cause an additional 20%.

HPV types 16 and 18 also cause nearly 90% of anal cancers and a substantial proportion of vaginal, vulvar, and oropharyngeal cancers. Vaccination also protects against anogenital warts.
Adult vaccinations - HPV

• Every year in the US 33,700 women and men are diagnosed with a cancer caused by HPV infection. HPV vaccination could prevent more than 90% of these cancers.

• HPV vaccination prevents more than just cervical cancer. Vaccination can prevent uncomfortable testing and treatment, even for cervical pre-cancers.

• Every year in the US, nearly 300,000 women are diagnosed with high grade cervical lesions. Testing and treatment for these pre-cancers can have lasting effects.
Subsequent vaccinations - HPV

HPV also causes cancers of:
✓ The penis in men
✓ Cancers of the vagina and vulva in women
✓ Cancers of the anus
✓ Cancers of the oropharynx in men and women.

While doctors routinely screen for cervical cancer, there are no recommended cancer screening tests for the other types of cancers caused by HPV infections.

These cancers may not be detected until they cause health problems.
The potential benefits of HPV vaccination appear to be cost effective for the recommended age range. One study suggested that vaccination of the entire United States population of 12-year-old girls would:

- Annually prevent more than 200,000 HPV infections
- 100,000 abnormal cervical cytology examinations
- 3,300 cases of cervical cancer
RATIONALE

**Males** — HPV vaccination provides a direct benefit to male recipients by safely protecting against cancers that can result from HPV infection.

HPV types 16 and 18 cause nearly 90% of anal cancers and substantial proportion of oropharyngeal and penile cancers. Vaccination also protects against anogenital warts (90% HPV types 6 and 11).

The overall burden of HPV-associated cancers/precancers among males is less than the burden of cervical cancer in females. Nevertheless, despite a smaller direct absolute benefit of HPV vaccination in males compared with females, the overall benefit of vaccinating males outweighs its potential risks (population benefits from herd immunity and the documented safety of HPV vaccines).
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Bivalent (2vHPV)*</th>
<th>Quadrivalent (4vHPV)†</th>
<th>9-valent (9vHPV)§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand name</td>
<td>Cervarix</td>
<td>Gardasil</td>
<td>Gardasil 9</td>
</tr>
<tr>
<td>VLPs</td>
<td>16, 18</td>
<td>6, 11, 16, 18</td>
<td>6, 11, 16, 18, 31, 33, 45, 52, 58</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>GlaxoSmithKline</td>
<td>Merck and Co., Inc.</td>
<td>Merck and Co., Inc.</td>
</tr>
<tr>
<td>Manufacturing</td>
<td>Trichoplusia ni insect cell line infected with L1 encoding recombinant baculovirus</td>
<td>Saccharomyces cerevisiae (Baker’s yeast), expressing L1</td>
<td>Saccharomyces cerevisiae (Baker’s yeast), expressing L1</td>
</tr>
<tr>
<td>Adjuvant</td>
<td>500 µg aluminum hydroxide, 50 µg 3-O-desacyl-4’ monophosphoryl lipid A</td>
<td>225 µg amorphous aluminum hydroxyphosphate sulfate</td>
<td>500 µg amorphous aluminum hydroxyphosphate sulfate</td>
</tr>
</tbody>
</table>

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old

For Immediate Release  October 5, 2018
## Tetanus vaccine

### Tetanus +/- Pertusis

Recommended booster every 10 years, if no trauma!

If trauma in the first 5 years post vaccine, no further intervention needed. If trauma after 5 years of vaccine, booster advised.

<table>
<thead>
<tr>
<th>Previous doses of tetanus toxoid*</th>
<th>Clean and minor wound</th>
<th>All other wounds§</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tetanus toxoid-</td>
<td>Human tetanus</td>
</tr>
<tr>
<td></td>
<td>containing vaccine Δ</td>
<td>immune globulin</td>
</tr>
<tr>
<td>&lt;3 doses or unknown</td>
<td>Yes $^5$</td>
<td>No</td>
</tr>
<tr>
<td>≥3 doses</td>
<td>Only if last dose given ≥10 years ago</td>
<td>No</td>
</tr>
</tbody>
</table>

---

* Tetanus toxoid-containing vaccine Δ

---

* Human tetanus immune globulin

---

* Only if last dose given ≥10 years ago

---

* Only if last dose given ≥5 years ago $^4$
Tetanus Stats 2016-17

• The proportion of adults aged ≥19 years reporting having received any tetanus toxoid-containing vaccination during the past 10 years was 63.4%

• Among adults aged ≥19 years for whom Tdap vaccination could be assessed, increased from 2016 to 2017 overall and by age group.

• Among adults aged ≥19 years, white adults had higher coverage
Pregnancy vaccines

Pertussis
Recommended during each pregnancy!
27 to 36 week gestational age
Vaccination of household contacts

Influenza
Recommended during the influenza season
Only inactivated vaccines
Influenza (flu) is a contagious respiratory illness caused by influenza viruses. There are 3 types of Influenza:

- Influenza A
- Influenza B
- Influenza C
Every year, millions of people get the flu. The good news is that the seasonal flu vaccine can lower the risk of getting the flu by about half.

It mostly killed young adults with more than half of the deaths in people between 20-40 years old due to novel surface proteins on the virus.

The majority of deaths were from a secondary infection (bacterial pneumonia)

Spanish flu killed as many as 25 million in the first 25 weeks, whereas HIV/AIDS has killed 25 million in the first 25 years. It killed 2-20 % of those infected; normal rate is 0.1 %
NORMAL TRACHEAL MUCOSA

3 DAYS POST-INFECTION

Lycke and Norrby Textbook of Medical Virology 1983
ProThrombotic State?

NEJM January 2018
Acute MI in the initial 6 days
Reassortment between the RNA segments encoding haemagglutinin (HA) and neuraminidase (NA) produces virus with novel HA and NA subtype combinations, and this has preceded the emergence of pandemic strains.

15 x 9 = 135 possible strains
People at increased risk for complications

It’s especially important for people who are at high risk of developing complications from the flu to get the vaccine every year. People at high risk for complications from the flu include:

- Pregnant women — including women up to 2 weeks after the end of pregnancy
- Adults age 65 years and older
- Children younger than 5 years — and especially children younger than 2 years
- People with long-term health conditions like asthma, diabetes, or cancer
- People in long-term care or nursing homes
The formula for the influenza vaccine is updated every year on the basis of worldwide surveillance by the collaborating centers of the World Health Organization (WHO).

Advisory committees of the CDC and of the FDA review the information and select for inclusion those variants of the 3 prevalent viruses in the human population that are most likely to cause outbreaks in the upcoming season.
The current production system requires that the viruses used for vaccine production be selected in February-March of each year:

✓ It is not unusual for new variants to appear in the southern hemisphere after the vaccine formula for the northern hemisphere has been set and production has begun.

A new variant that was not contained in the vaccine has been the major virus involved in 80% of the epidemics.
Influenza Vaccine Effectiveness

Defining the problem

**Reduced protection**
- H3N2 – 33%
- H1N1 -- 62%
- Flu B – 54%

**Age dependent**
- For H3N2:
  - Pediatrics – 43%
  - Age > 60 – 24%

**Increase glycosylation**
- Original H3N2 (HK1968) had 2 glycosylation sites, but now has 6-7 sites in the HA site.
Who Needs Vaccination

Everybody from 6 months old

All pregnant female should be assess for vaccination.

✓ Vaccine is safe in pregnancy
✓ Decreases disease in mother and baby

Vaccines DOSES NOT increase risk of Guillain-Barre
• Healthcare workers vaccination is associated with:
  ✓ Decrease in missing work
  ✓ Decrease influenza death in patients

• There is also strong correlation to decrease HCW-patient transmission:
  ✓ Patient exposed to HCW – RR 5.48
  ✓ Patient exposed to contagious patient – RR 17.96
  ✓ Patient exposed to HCW and contagious patient – 34.75

✓ Always use PPE despite receiving vaccination.
## Vaccines 2019

Basics of influenza vaccine: not all vaccines are the same.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Component</th>
<th>Age Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trivalent SD</td>
<td>H3N2, H1N1, B</td>
<td>18-64 years old</td>
</tr>
<tr>
<td>Trivalent HD</td>
<td>H3N2, H1N1, B</td>
<td>65 plus years old</td>
</tr>
<tr>
<td>Recombinant Egg-free</td>
<td>H3N2, H1N1, B</td>
<td>18 plus years old</td>
</tr>
<tr>
<td>Trivalent w/ adjuvant</td>
<td>H3N2, H1N1, B</td>
<td>65 plus years old</td>
</tr>
<tr>
<td>Quadrivalent</td>
<td>H3N2, H1N1, Bx2</td>
<td>Different age groups</td>
</tr>
<tr>
<td>Quadrivalent intradermal</td>
<td>H3N2, H1N1, Bx2</td>
<td>18 plus years old</td>
</tr>
<tr>
<td>Quadrivalent Cell-cultured</td>
<td>H3N2, H1N1, Bx2</td>
<td>4 plus years old</td>
</tr>
<tr>
<td>Quadrivalent Nasal Spray</td>
<td>H3N2, H1N1, Bx2</td>
<td>AGAIN RECOMMENDED</td>
</tr>
</tbody>
</table>
## Influenza Vaccine Side Effects

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Vaccine (%)</th>
<th>Placebo (%)</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>5.7</td>
<td>4.2</td>
<td>.68</td>
</tr>
<tr>
<td>Cough</td>
<td>6.6</td>
<td>5.1</td>
<td>.62</td>
</tr>
<tr>
<td>Coryza</td>
<td>13.2</td>
<td>10.2</td>
<td>.27</td>
</tr>
<tr>
<td>Fatigue</td>
<td>8.0</td>
<td>7.7</td>
<td>.82</td>
</tr>
<tr>
<td>Malaise</td>
<td>7.2</td>
<td>6.3</td>
<td>.83</td>
</tr>
<tr>
<td>Myalgia</td>
<td>4.8</td>
<td>4.2</td>
<td>.84</td>
</tr>
<tr>
<td>Headache</td>
<td>6.9</td>
<td>7.6</td>
<td>.99</td>
</tr>
<tr>
<td>Any symptom</td>
<td>27.7</td>
<td>22.9</td>
<td>.21</td>
</tr>
<tr>
<td>Sore arm</td>
<td>20.1</td>
<td>4.9</td>
<td>$&lt;.001$</td>
</tr>
</tbody>
</table>
Practice Standards for All Healthcare Professionals

1. ASSESS immunization status of all your patients at every clinical encounter.
   - Follow yearly updates at www.CDC.gov

2. Strongly RECOMMEND vaccines that patients need.
   - Share tailored reasons why vaccination is right for the patient.
   - Highlight positive experiences with vaccination.
   - Address patient questions and concerns.
   - Remind patients that vaccines protect them and their loved ones against a number of common and serious diseases.
   - Explain the potential costs of getting sick.
Practice Standards for All Healthcare Professionals

3. ADMINISTER or REFER your patients to a vaccination provider.
   - Offer the vaccines you stock.
   - Refer patients to providers in the area that offer vaccines that you don’t stock.

4. DOCUMENT vaccines received by your patients.

   ✓ **Participate in your state’s immunization registry.** Help your office, your patients, and your patients’ other providers know which vaccines your patients have had.

   ✓ **Follow up.** Confirm that patients received recommended vaccines that you referred them to get from other immunization providers.
Dengvaxia (live attenuated tetravalent chimeric vaccine)
*3 doses
*Recommended age 9-16 years
*only in persons with laboratory confirmed

Why? ADE
✓ ADE (antibody-dependent enhancement of infection) Phenomenon
DENGVAXIA

Limitations of use:
• Not approved for use in individuals not previously infected by any dengue virus serotype. Those not previously infected are at increased risk for severe dengue disease when vaccinated.

Warning:
• In persons not previously infected by dengue virus, an increased risk of severe dengue disease can occur following vaccination with DENGVAXIA.

• There is no FDA-cleared test available to determine a previous dengue infection.
Dengue Vaccine in pipeline...

- TetraVax-DV – Brasil
- TDENV PIV – GSK with Walter Reed Army Institute of Research
- V180 – MERCK

Should we vaccinate or wait further options?
The German company BioNTech partnered with Pfizer to develop and test a coronavirus vaccine known as BNT162b2, the generic name tozinameran or the brand name Comirnaty.

- Vaccine based on mRNA.

- A clinical trial demonstrated that the vaccine has an efficacy rate of 95% in preventing Covid-19.
A Piece of the Coronavirus

The SARS-CoV-2 virus is studded with proteins that it uses to enter human cells. These so-called spike proteins make a tempting target for potential vaccines and treatments.

Like the Moderna vaccine, the Pfizer-BioNTech vaccine is based on the virus’s genetic instructions for building the spike protein.

mRNA Inside an Oily Shell

The vaccine uses messenger RNA, genetic material that our cells read to make proteins. The molecule — called mRNA for short — is fragile and would be chopped to pieces by our natural enzymes if it were injected directly into the body. To protect their vaccine, Pfizer and BioNTech wrap the mRNA in oily bubbles made of lipid nanoparticles.

Because of their fragility, the mRNA molecules will quickly fall apart at room temperature. Pfizer is building special containers with dry ice, thermal sensors and GPS trackers to ensure the vaccines can be transported at -94°F (-70°C) to stay viable.
Entering a Cell

After injection, the vaccine particles bump into cells and fuse to them, releasing mRNA. The cell’s molecules read its sequence and build spike proteins. The mRNA from the vaccine is eventually destroyed by the cell, leaving no permanent trace.
Spotting the Intruder

When a vaccinated cell dies, the debris will contain many spike proteins and protein fragments, which can then be taken up by a type of immune cell called an antigen-presenting cell.
Making Antibodies

Other immune cells, called B cells, may bump into the coronavirus spikes on the surface of vaccinated cells, or free-floating spike protein fragments. A few of the B cells may be able to lock onto the spike proteins. If these B cells are then activated by helper T cells, they will start to proliferate and pour out antibodies that target the spike protein.
Stopping the Virus

The antibodies can latch onto coronavirus spikes, mark the virus for destruction and prevent infection by blocking the spikes from attaching to other cells.
Killing Infected Cells

The antigen-presenting cells can also activate another type of immune cell called a killer T cell to seek out and destroy any coronavirus-infected cells that display the spike protein fragments on their surfaces.
A Piece of the Coronavirus

The SARS-CoV-2 virus is studded with proteins that it uses to enter human cells. These so-called spike proteins make a tempting target for potential vaccines and treatments.

DNA Inside an Adenovirus

The researchers added the gene for the coronavirus spike protein to another virus called Adenovirus 26. Adenoviruses are common viruses that typically cause colds or flu-like symptoms. The Johnson & Johnson team used a modified adenovirus that can enter cells but can't replicate inside them or cause illness.
Building Spike Proteins

The mRNA leaves the nucleus, and the cell's molecules read its sequence and begin assembling spike proteins.
The present is bright, and the future even brighter

- HPV
  - Cervical CA
  - Rectal CA
- HBV
  - HCC
- Influenza
  - Myocardial infarction
  - CVA

Pipeline
- Dengue
- Zika
- Malaria
- HCV
- CMV
- HIV
- Universal influenza
Live, attenuated influenza vaccine (LAIV) is an option for adults through age 49 years, except those who:

- **Immunosuppressed** (including HIV)
- Have anatomical or functional asplenia
- Are pregnant
- Have close contact with or are caregivers of severely immunocompromised persons in a protected environment
- Have received influenza antiviral medications in the previous 48 hours
- Have a cerebrospinal fluid leak or a cochlear implant
Live vaccines

- Adenovirus vaccine
- Bacille Calmette-Guérin (BCG)
- Live attenuated influenza vaccine (intranasal)*
- Live attenuated oral poliovirus vaccine*
- Measles, mumps, and rubella vaccine
- Measles, mumps, rubella, and varicella vaccine
- Measles vaccine
- Mumps vaccine
- Oral typhoid vaccine*
- Rotavirus vaccine
- Rubella vaccine
- Smallpox vaccine
- Varicella vaccine
- Yellow fever vaccine
- Zoster vaccine

In the United States, live virus vaccines are routinely recommended for protection against rotavirus, measles, mumps, rubella, varicella, and herpes zoster. Either inactivated or live attenuated influenza vaccine may be used for people 2 through 49 years of age. Oral poliovirus vaccine is not available in the United States. Routinely recommended vaccines for other countries are available through the World Health Organization. Refer to the relevant UpToDate topic reviews for specific vaccine recommendations.
Vaccine Contraindication

Moderate to severe illness with or without fever

History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine

History of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of IIV and LAIV.

ACIP recommends that any licensed, recommended, and appropriate IIV or RIV may be administered to persons with egg allergy of any severity